Does Medicaid cover Ozempic in New York?

If you’ve been considering a GLP-1 medication like Wegovy, Ozempic, or Mounjaro for weight loss or diabetes management, you’re probably wondering: Will my insurance cover it? The answer isn’t straightforward—and for many Americans, navigating the maze of prior authorizations, formulary restrictions, and state-by-state Medicaid rules can feel overwhelming.

The truth is, insurance coverage for these breakthrough medications varies dramatically depending on whether you have commercial insurance, Medicare, or Medicaid, what state you live in, and whether you’re using the drug for diabetes or weight loss. As of December 2025, the landscape is shifting rapidly—some states are cutting coverage due to budget pressures, while new manufacturer discount programs are making self-pay options more accessible than ever.

In this comprehensive guide, we’ll break down exactly what you need to know about GLP-1 insurance coverage, including which medications are covered under different plans, how to navigate prior authorization requirements, what to do if you’re denied, and the best cash-pay alternatives if insurance won’t help.

Understanding GLP-1 Medications: What’s the Difference?

Before diving into coverage, let’s clarify what these medications are and how they differ:

Wegovy (semaglutide) is FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight individuals (BMI ≥27) with at least one weight-related condition like high blood pressure or Type 2 diabetes.

Ozempic (semaglutide) is FDA-approved for Type 2 diabetes management and reducing cardiovascular risk in certain patients. While it’s the same active ingredient as Wegovy at different doses, insurance will not cover Ozempic for weight loss—that’s considered off-label use.

Mounjaro (tirzepatide) is approved for Type 2 diabetes. Its sister drug, Zepbound (also tirzepatide), is the version approved for weight loss, but Mounjaro itself is covered only for diabetes treatment.

This distinction matters enormously for insurance purposes. Most plans readily cover diabetes medications but exclude or severely restrict weight-loss drugs—even when it’s the exact same molecule.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: The Complex Reality

Diabetes Coverage (Ozempic & Mounjaro)

If you have Type 2 diabetes, the news is generally positive. Most commercial insurance plans cover Ozempic and Mounjaro as part of their standard diabetes medication formulary. These drugs are considered essential treatments for blood sugar control and cardiovascular risk reduction.

However, coverage doesn’t mean automatic approval. Insurers typically require:

• Prior authorization to confirm your diabetes diagnosis
• Documentation that first-line treatments (usually metformin) haven’t adequately controlled your blood sugar
• Evidence of an A1c level above target range
• In some cases, proof that you’ve tried another GLP-1 or diabetes medication first

Typical tier placement: Tier 3 (non-preferred brand) or Tier 4 (specialty), meaning your copay could range from $50–$150 per month with insurance, though some plans charge a percentage (coinsurance) instead—often 20–30% of the drug’s cost.

The prior authorization process usually takes 5–7 business days. Your healthcare provider submits clinical documentation, and if criteria are met, approval is straightforward. Most denials for diabetes use stem from incomplete paperwork rather than true ineligibility.

Weight Loss Coverage (Wegovy)

This is where things get complicated. Many employer-sponsored health plans exclude anti-obesity medications entirely due to cost concerns. Those that do cover Wegovy impose strict requirements:

Common prior authorization criteria include:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, Type 2 diabetes, high cholesterol, sleep apnea)
• Age ≥18 years
• Documentation of at least 6 months of supervised diet and exercise attempts with insufficient weight loss
• Sometimes, proof that you’ve tried older, cheaper weight-loss medications first
• Commitment to ongoing lifestyle modification program

According to Aetna’s May 2024 clinical policy, patients must demonstrate they’ve participated in a structured weight management program and failed to achieve meaningful weight loss before Wegovy will be considered. Even with approval, coverage may be limited to an initial 3–6 month trial, with continuation requiring proof of at least 5% body weight loss.

Large insurers like Cigna and Aetna follow similar protocols, reflecting an industry-wide approach to managing the high cost of these medications—around $1,350 per month at list price for Wegovy.

What About Medicare?

Medicare Part D does not cover drugs prescribed solely for weight loss—this is written into federal law. Anti-obesity medications are among the categories Medicare is prohibited from covering.

There’s one important exception: In March 2024, Medicare announced it would cover Wegovy only for patients with established cardiovascular disease who are using it to reduce heart attack and stroke risk. This followed FDA’s expanded approval for Wegovy’s cardiovascular benefits. But if you’re a Medicare beneficiary seeking Wegovy purely for weight management, you’re out of luck unless you qualify under the cardiovascular indication.

Medicare does cover Ozempic and Mounjaro for Type 2 diabetes, treating them like other diabetes medications with typical Part D cost-sharing (deductibles, copays in the coverage gap, etc.). Prior authorization varies by plan.

State-by-State Medicaid Coverage: A Patchwork System

Medicaid coverage for GLP-1 weight-loss medications is perhaps the most inconsistent aspect of the insurance landscape. States have the option to cover anti-obesity drugs, but as of 2024, only about 13 states chose to do so—and that number is shrinking.

California: Coverage Ending January 1, 2026

California’s Medi-Cal briefly covered Wegovy with prior authorization in 2025, requiring BMI ≥30 (or ≥27 with comorbidities) and documented diet attempts. But in December 2025, California announced it will discontinue coverage for all GLP-1 weight-loss medications effective January 1, 2026 due to budget constraints. Pediatric patients may still access coverage through EPSDT (Early and Periodic Screening, Diagnostic and Treatment) provisions, but adult coverage is ending.

Texas: No Coverage

Texas Medicaid does not cover any obesity medications for adults (age 21+), including Wegovy, Saxenda, or Zepbound. This exclusion has been in place since at least March 2023. Children under 21 may request case-by-case exceptions through EPSDT, but the state’s policy explicitly excludes weight-loss drugs from its formulary for adults.

Florida: No Coverage

Florida Medicaid follows the federal optional exclusion for weight-loss drugs and does not include Wegovy or similar medications on its preferred drug list. Only GLP-1s approved for diabetes (like Ozempic) are covered, and strictly for diabetes treatment.

New York: Covered with Strict Prior Authorization

New York’s Medicaid program does cover Wegovy, but requires extensive documentation through its prior authorization process. Patients must meet FDA labeling criteria (BMI thresholds, comorbidities), prove lifestyle intervention attempts, and maintain compliance with ongoing treatment requirements. Quantity limits (typically 4 pens per 28 days) apply.

Pennsylvania: Coverage Ending Soon

Pennsylvania Medicaid added Wegovy coverage in 2023 with requirements including BMI ≥30 (or ≥27 + comorbidities), documented weight-related conditions, and evidence of diet/exercise attempts. Patients with diabetes were required to try a diabetes-indicated GLP-1 first. However, in December 2025, Pennsylvania announced it will stop covering GLP-1 weight-loss drugs in January 2026 due to cost pressures, similar to California.

Illinois: No Coverage

Illinois Medicaid does not cover Wegovy or other anti-obesity medications for Medicaid enrollees (as of 2025), despite the state expanding coverage for state employees in 2023.

The trend is clear: Even states that initially embraced coverage of these medications are pulling back as budget impacts become apparent. The high cost—often $1,000+ per patient per month—is straining state Medicaid budgets, especially as demand surges.

Understanding Prior Authorization: What Insurers Want to See

Whether you have commercial insurance or Medicaid in a state that covers GLP-1s, prior authorization is almost universal. Here’s what you and your provider need to demonstrate:

For Weight Loss (Wegovy):

1. Documented BMI meeting threshold (usually ≥30 or ≥27 with comorbidities)
2. Weight-related comorbidities such as:

• Type 2 diabetes or prediabetes
• Hypertension
• High cholesterol
• Obstructive sleep apnea
• Cardiovascular disease

1. Supervised weight-loss attempts: Most insurers require 6+ months of documented diet and exercise programs that didn’t achieve sufficient weight loss
2. Commitment to ongoing lifestyle modification: Including nutritional counseling and regular physical activity
3. Age requirement: Typically 18+ (some plans 12+ for pediatric obesity)

For Diabetes (Ozempic, Mounjaro):

1. Confirmed Type 2 diabetes diagnosis
2. A1c level documentation (usually must be above target despite current treatment)
3. Trial of first-line therapy: Evidence you’ve tried metformin or another appropriate diabetes medication first (unless contraindicated)
4. Clinical justification for choosing a GLP-1 over other options

Your healthcare provider submits these details along with your prescription. The insurer reviews against their medical policy criteria, typically responding within 5–7 business days for standard requests (24–72 hours for urgent requests).

Common Reasons for Denial—And How to Appeal

Why Claims Get Denied

1. Medical Necessity Not EstablishedThe most common denial reason. Your documented BMI might be just below the threshold, or required comorbidities aren’t clearly noted in your medical record.

2. Insufficient DocumentationNo record of supervised diet/exercise program, or the documentation doesn’t span the required 6-month period. Insurance reviewers are looking for detailed notes from your provider showing ongoing weight management efforts.

3. Step Therapy Not CompletedFor diabetes, you may not have tried required first-line treatments. For obesity, some plans require trying older, cheaper weight-loss medications (like phentermine or orlistat) before approving a GLP-1.

4. Off-Label UseRequesting Ozempic for weight loss when you don’t have diabetes, or Mounjaro for obesity when Zepbound is the approved formulation for that use. Insurers will deny coverage for non-FDA-approved indications.

5. Plan ExclusionYour insurance policy may explicitly exclude ‘drugs used for weight control or weight loss’ as a category. If so, no amount of medical justification will result in coverage unless your employer negotiated an exception.

How to Appeal Successfully

If your prior authorization is denied, don’t give up. Appeal success rates vary but can be significant when you truly meet criteria.

Steps to appeal:

1. Request a detailed denial letter explaining the specific reason(s) for rejection
2. Work with your provider to gather missing documentation or address gaps
3. Submit a letter of medical necessity from your doctor explaining why this medication is essential for your health, citing clinical guidelines and your individual circumstances
4. Include supporting evidence: Weight history, documentation of previous attempts, lab results showing comorbidities, notes from nutrition or lifestyle programs
5. Cite peer-reviewed research if appropriate, demonstrating the medication’s effectiveness for your condition
6. Follow your insurer’s appeal timeline: Usually you have 30–60 days to file an appeal; some plans offer expedited appeals

For commercially insured patients with severe obesity (BMI ≥35) and established health risks, appeals with thorough documentation often succeed, especially when the provider makes a compelling case that less expensive alternatives have failed.

Important note: If your plan has a categorical exclusion of obesity drugs, internal appeals rarely work. However, if your employer is self-insured, you may be able to request they make an exception for coverage—this requires going beyond the insurance administrator.

Telehealth and Insurance: Virtual Care Is Covered

Here’s some good news: Insurance generally covers telehealth consultations for weight management and diabetes care just as it would in-person visits.

Since the COVID-19 pandemic, most major health plans and Medicare have permanently expanded telehealth coverage. Over 40 states have enacted parity laws requiring private insurers to cover telehealth services equivalently to in-person care. This means:

• Virtual appointments with your doctor or specialist for weight-loss treatment count toward your supervised program documentation
• Nutritional counseling sessions via video are covered as preventive care under the Affordable Care Act
• Follow-up visits to monitor your progress on a GLP-1 can be conducted remotely

Coverage considerations:

• You typically need to use an in-network provider for coverage to apply
• Most plans require live video for the visit to qualify (phone-only or asynchronous messaging may not be covered)
• Some platforms operate on a cash-pay basis for the visit even if they can prescribe medications covered by your insurance

Klarity Health makes accessing care straightforward—our platform connects you with experienced healthcare providers who understand the nuances of GLP-1 prescribing and insurance requirements. We accept both insurance and cash pay, with transparent pricing so you know your costs upfront. Our providers have extensive availability for virtual visits, making it easier to maintain the regular follow-ups insurers require for continued approval.

Self-Pay Options: What If Insurance Won’t Cover It?

If your insurance denies coverage or you’re uninsured, there are several ways to access GLP-1 medications more affordably than the $1,000+ monthly list price.

Manufacturer Savings Programs

Novo Nordisk (Wegovy & Ozempic):

• Savings Card for commercially insured patients: Can reduce copay to as low as $0 (up to $225 off per month). Must have insurance coverage of the drug to qualify.
• NovoCare Wegovy Access Program: Self-pay price reduced to $349/month (down from $499) as of November 2025.
• Patient Assistance Program: Free medication for uninsured or under-insured individuals meeting income criteria (typically <400% of federal poverty level).

Eli Lilly (Mounjaro & Zepbound):

• Savings Card: $25/month for commercially insured patients with Type 2 diabetes (covers up to $500 of the cost).
• LillyDirect program: Single-dose vials of Zepbound at $299–$449/month depending on dose, with home delivery.
• Patient Assistance Program: Free medication for qualifying low-income patients.

GoodRx Partnership Programs

In November 2025, GoodRx announced a game-changing partnership with Novo Nordisk:

• Introductory pricing: Wegovy or Ozempic for just $199/month for the first two months
• Ongoing pricing: $349/month for most doses at participating pharmacies nationwide
• Weight Loss Telemedicine Subscription: $39/month for ongoing virtual care support

This represents a 60–70% discount off typical retail prices and is available to anyone—no insurance required.

Comparing Self-Pay Prices

What about compounded semaglutide?

Some telehealth and wellness clinics offer compounded versions of semaglutide or tirzepatide at lower prices (sometimes $200–$400/month). While tempting, these are not FDA-approved products. Compounded medications aren’t held to the same safety, efficacy, and quality standards as brand-name drugs. The FDA has issued warnings about the risks of compounded GLP-1s, including incorrect dosing and contamination concerns.

Other Lower-Cost Alternatives

If GLP-1s remain out of reach financially, consider discussing these older weight-loss medications with your provider:

• Phentermine: Generic, typically $30–$100/month
• Orlistat (Xenical/Alli): Generic available, ~$50–$100/month
• Phentermine-Topiramate (Qsymia): Brand only, but some insurance covers it; ~$200/month cash-pay

While these aren’t as effective as GLP-1s for most patients, they’re proven weight-loss tools that might be covered by your insurance or more affordable out-of-pocket.

Making the Coverage Matrix Work for You

Here’s a practical action plan based on your insurance type:

If You Have Commercial Insurance:

1. Check your formulary: Log into your insurance portal and search for Wegovy, Ozempic, or Mounjaro to see if they’re covered and at what tier
2. Review your plan’s exclusions: Look for language about ‘weight control’ or ‘obesity’ drugs
3. Contact your HR benefits department if it’s an employer plan—they can clarify coverage and may advocate for exceptions
4. Work with your provider to start building the documentation trail now (weight history, comorbidity diagnoses, lifestyle program participation)
5. Be prepared for prior authorization: Expect the process to take 1–2 weeks
6. Have a backup plan: Know what you’ll do if denied (appeal vs. cash-pay options)

If You Have Medicare:

1. For diabetes: Coverage should be available for Ozempic or Mounjaro with your Part D plan
2. For weight loss: Coverage is extremely limited unless you qualify under cardiovascular indications for Wegovy
3. Consider Medicare Advantage: Some MA plans have begun offering limited obesity drug coverage as supplemental benefits in 2025
4. Explore manufacturer assistance: Patient assistance programs don’t discriminate based on insurance type

If You Have Medicaid:

1. Check your state’s status: Use our state table above or contact your Medicaid office
2. If your state doesn’t cover: Look into manufacturer patient assistance programs, which are designed for low-income patients
3. For children under 21: EPSDT provisions may allow coverage even in states that don’t cover adults
4. Monitor policy changes: Several states are adjusting coverage in 2026

If You’re Uninsured or Coverage Is Denied:

1. Apply for manufacturer patient assistance: Both Novo Nordisk and Eli Lilly have programs for qualifying patients
2. Use the new GoodRx discount programs: The $199–$349 pricing makes Wegovy/Ozempic significantly more accessible
3. Consider Klarity Health: Our cash-pay pricing is transparent, and we can help you navigate the most cost-effective options
4. Budget for long-term treatment: Weight-loss medications work best when continued long-term, so plan for sustained costs
5. Compare total costs: Sometimes paying $349/month cash is less expensive than a high insurance copay or deductible

The Bottom Line: Coverage Is Complicated, But Options Exist

So, does insurance cover Wegovy, Ozempic, or Mounjaro? The honest answer is: it depends—on your insurance type, your diagnosis, your state (for Medicaid), and your specific plan’s policies.

What we know for certain:

✅ Diabetes coverage for Ozempic and Mounjaro is widely available through commercial insurance and Medicare, though prior authorization is standard

✅ Weight-loss coverage for Wegovy remains limited in commercial insurance, requires extensive documentation when available, and is nearly non-existent in Medicare

✅ Medicaid coverage varies dramatically by state and is shrinking as budget pressures mount

✅ Self-pay options have improved dramatically in late 2025, with manufacturer discounts and GoodRx partnerships making these medications more accessible than ever at $199–$349/month

✅ Telehealth is covered for weight-loss and diabetes consultations by most insurers, making ongoing care more convenient

The key is to be proactive. Start the conversation with your healthcare provider early, understand your insurance’s specific requirements, and begin building the documentation trail before you even request the medication. If denied, appeal with comprehensive supporting evidence. And if insurance ultimately won’t help, know that the cash-pay landscape has changed significantly—what was once a $1,350/month barrier is now potentially $349/month, which, while still substantial, is within reach for many patients seeking effective weight management.

At Klarity Health, we understand how frustrating insurance barriers can be. Our providers are experienced in navigating prior authorization requirements and can work with you to build the strongest possible case for coverage. And if insurance isn’t an option, we offer transparent cash-pay pricing and accept both insurance and self-pay patients. With excellent provider availability and virtual care that fits your schedule, we’re here to help you access the treatment you need without the runaround.

The landscape of GLP-1 coverage will continue evolving. Manufacturer pressures to lower costs, potential legislative changes to Medicare and Medicaid coverage, and growing recognition of obesity as a serious chronic disease may expand access over time. But you don’t have to wait—effective options exist today, whether through insurance or affordable self-pay programs.

Ready to explore your options? Klarity Health’s experienced providers can help you determine the best path forward—whether that’s navigating insurance coverage, finding manufacturer assistance programs, or accessing affordable cash-pay options. Schedule a virtual consultation today to discuss your weight-loss or diabetes management goals.

📅 Research Currency Statement

Verified coverage status and pricing are accurate as of December 17, 2025. Always check your own insurance formulary for the latest details, as policies can change with new plan years.

Formularies checked:

• Aetna Clinical Policy (May 2024)
• Cigna Formulary (April 2024)
• Kaiser Permanente update (Jan 2025)
• Texas VDP criteria (Mar 2023)
• Pennsylvania Medicaid bulletin (Aug 2024)

Medicaid formularies verified:

• California DHCS (Dec 2025)
• Texas HHSC (Mar 2023)
• Florida (federal exclusion confirmed)
• New York NYRx PDL (Oct 2025)
• Pennsylvania DHS (Dec 2025)
• Illinois HFS (no coverage as of 2025)

GoodRx prices as of: Dec 2025, including Novo Nordisk/NovoCare program (effective Nov 2025), GoodRx press release (Nov 17, 2025), and Lilly pricing updates (Dec 2025).

References

1. Aetna Clinical Policy Bulletin – Weight Loss GLP-1 Agonists (www.aetna.com) – May 2024
2. California DHCS Medi-Cal Announcement (www.cmadocs.org) – December 2025
3. Forbes – Medicaid Plans Lag on Weight-Loss Drugs (www.forbes.com) – August 7, 2025
4. KFF Issue Brief – Medicaid Coverage of GLP-1s (www.kff.org) – November 4, 2024
5. Reuters News – Medicare to cover Wegovy for Heart Disease (www.reuters.com) – March 21, 2024
6. Texas HHSC Provider Alert – Obesity Drug Exclusion (www.texaschildrenshealthplan.org) – April 28, 2023
7. Pennsylvania Health Law Project (www.phlp.org) – 2024
8. WESA (NPR) Pittsburgh – PA Medicaid Coverage Changes (www.wesa.fm) – December 4, 2025
9. GoodRx Press Release via BusinessWire (www.businesswire.com) – November 17, 2025
10. Fierce Pharma – Novo & Lilly Cut Self-Pay Prices (www.fiercepharma.com) – November & December 2025

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499